Ethics of Drug Research and Drug Development

  • H.-M. Sass
Part of the Bayer AG Centenary Symposium book series (BAYER)


Medical benefits of clinical research during the past hundred years include effective vaccines and drugs for fighting most infections, the virtual eradication of epidemic diseases such as smallpox and cholera, an impressive reduction in infant mortality and the prevention of diseases such as polio and pertussis, transplantation of vital organs such as heart, kidneys, and liver, and impressively improved life-expectancy rates for patients suffering stroke, heart disease, or cancer. Life expectance overall has increased impressively and medical benefits can easily be translated into social, economic, cultural, and moral benefits. Quantitative and qualitative evidence regarding the impact of the result of clinical investigations in everyday life suggests that clinical research is not only morally acceptable, but morally mandated [1, 23, 25].


Drug Development Human Experimentation Drug Research Risk Awareness Moral Design 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beecher HK (1966) Ethics and clinical research. N Engl J Med 274: 1354–1360PubMedCrossRefGoogle Scholar
  2. 2.
    Brewin TB (1982) Consent to randomized treatment. Lancet II: 919–921CrossRefGoogle Scholar
  3. 3.
    Engelhardt HT (1988) Diagnosing well and treating prudently. In: Spicker SF, et al. (eds) The use of human beings in research. Kluwer, Dordrecht, pp 123–141CrossRefGoogle Scholar
  4. 4.
    Fagot-Largeault AM (1988) Epitemological presuppositions involved in the programs of human research. In: Spicker SF, et al. (ed) The use of human beings in research. Kluwer, Dordrecht, pp 161–187CrossRefGoogle Scholar
  5. 5.
    Feinstein AR (1967) Clinical judgement. Krieger, HuntingtonGoogle Scholar
  6. 6.
    Feinstein AR (1977) Clinical biostatistics. Mosby, St. LouisGoogle Scholar
  7. 7.
    Freedman B (1987) Equipoise and the ethics of clinical research. N Engl J Med 317 (3): 141–145PubMedCrossRefGoogle Scholar
  8. 8.
    Freireich EJ (1988) Ethical issues in clinical trials. Biomed Pharmacother 42: 157–158PubMedGoogle Scholar
  9. 9.
    Gehan EA (1988) Methodological issues in cancer clinical trials: the comparison of therapies. Biomed Pharmacother 42: 161–165PubMedGoogle Scholar
  10. 10.
    Gifford F (1986) The conflict between randomized clinical trials and the therapeutic obligation. J Med Philos 11: 347–366PubMedGoogle Scholar
  11. 11.
    Gray BH (1975) Human subjects in medical experimentation. Wiley, New YorkGoogle Scholar
  12. 12.
    Guyatt G, Sackett D, et al. (1986) Determining optimal therapy–randomized trials in individual patients. N Engl J Med 314 (14): 889–892PubMedCrossRefGoogle Scholar
  13. 13.
    Helsinki/Tokyo Declaration on Biomedical Research 1975 (1978) In: Reich WT (ed) Encyclopedia of bioethics, vol 4. Macmillan, London, pp 1771–1773Google Scholar
  14. 14.
    Hurst J (1987) New attitudes in assessing benefits. In: Smith GT (ed) Costs and benefits of pharmaceutical research. Office of Health Economics, London, pp 18–24Google Scholar
  15. 15.
    Kadane JB (1986) Progress toward a more ethical method for clinical trials. J Med Philos 11: 385–404PubMedGoogle Scholar
  16. 16.
    Koppelman L (1986) Consent or randomized clinical trials: are there moral or design problems? J Med Philos 11: 317–345Google Scholar
  17. 17.
    Kos Statement on Randomization 1986/1987 (1988) Biomed Pharmacother 42: 167Google Scholar
  18. 18.
    Marquis D (1986) An argument that all prerandomized clinical trials are unethical. J Med Philos 11: 367–383PubMedGoogle Scholar
  19. 19.
    Mathe G, Brienza S (1988) From methodology to ethics and from ethics to methodology. Biomed Pharmacother 42: 143–153PubMedGoogle Scholar
  20. 20.
    Moroff SV (1986) Qualitative and ethical issues in quantitative clinical decision-making. NY State J Med 86: 250–253Google Scholar
  21. 21.
    Moser M (1986) Randomized clinical trials: problems and values. Am J Emerg Med 4 (2): 173–178PubMedCrossRefGoogle Scholar
  22. 22.
    Sass HM (1983) Reichsrundschreiben 1931, Pre-Nuremberg regulations concerning new therapy and human experimentation. J Med Philos 8: 101–113Google Scholar
  23. 23.
    Sass HM (1987) Philosophical and moral aspects of manipulation and risk. Swiss Biotech 5 (2a): 50–56PubMedGoogle Scholar
  24. 24.
    Sass HM (1988) Comparative models and goals for the regulation of human research. In: Spicker SF, et al. (ed) The use of human beings in research. Kluver, Dordrecht, pp 47–89CrossRefGoogle Scholar
  25. 25.
    Sass HM (1989) Ethische Kosten-Nutzen Analyse. Zentrum für Medizinische Ethik Bochum, Medizinethische Materialien No. 22Google Scholar
  26. 26.
    Sass HM (1989a) Brainlife and braindeath. J Med Philos 14: 45–59PubMedGoogle Scholar
  27. 27.
    Sass HM (1989b) Blue-ribbon commissions and political ethics in the Federal Republic of Germany. J Med Philos 14 (4) (in print)Google Scholar
  28. 28.
    Sassower R, Grodin MA (1987) Scientific uncertainty and medical responsibility. Theor Med 8: 221–234PubMedCrossRefGoogle Scholar
  29. 29.
    Schaffner KF (1986) Ethical problems in clinical trials. J Med Philos 11: 297–315PubMedGoogle Scholar
  30. 30.
    Spicker SF (1988) Research risks, randomization, and risk to research. In: Spicker SF, et al. (ed) The use of human beings in research. Kluwer, Dordrecht, pp 143–160CrossRefGoogle Scholar
  31. 31.
    US Department of Health and Human Services (1987) Investigational new drug, antibiotic, and biological drug product regulations (21 CFR part 312). Federal Register 52 (no 99), pp 19466–77Google Scholar
  32. 32.
    US President’s Commission (1983) Implementing human research regulations ( 83600504 ). Government Printing Office, Washington DCGoogle Scholar
  33. 33.
    von Eickstedt KW (1983) The ethical position of the attending physician in phase III of clinical investigations. Int J Clin Pharm Ther Toxicol 21 (10): 529–534Google Scholar
  34. 34.
    Zelen M (1979) A new design for randomized clinical trials. New Engl J Med 300: 1242–1245PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • H.-M. Sass
    • 1
  1. 1.Institut für PhilosophieRuhr-Universität Bochum, Fakultät für Philosophie, Pädagogik und PublizistikBochum 1Federal Republic of Germany

Personalised recommendations